as 12-11-2024 4:00pm EST
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | BOSTON |
Market Cap: | 29.5M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 80.5K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.46 | EPS Growth: | N/A |
52 Week Low/High: | $0.90 - $4.40 | Next Earning Date: | 11-19-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AKTX Breaking Stock News: Dive into AKTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
The information presented on this page, "AKTX Akari Therapeutics plc ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.